Dr. Papa on Leukapheresis Manufacturing Approach in Head and Neck Cancer

Sophie Papa, PhD, MBBS, MRCP
Published Online: Thursday, May 18, 2017



Sophie Papa, PhD, MBBS, MRCP, medical oncologist, Clinical Academic Group, Department of Research Oncology, King’s College London, discusses leukapheresis manufacturing approach in head and neck cancer.

In a study on CAR T cells in head and neck cancer, leukapheresis was done on patients. It allowed researchers to use CAR 4αβ that was co-expressed with the CAR to manufacture cell product with a 100% success rate to date, from as little to 14 mL of whole blood to normally 120 mL of whole blood.

This is an expensive manufacturing approach, though, and it takes a long time. But, in this trial, Papa says, it was done with a blood draw—less than what would be taken in a blood donation.
 


Sophie Papa, PhD, MBBS, MRCP, medical oncologist, Clinical Academic Group, Department of Research Oncology, King’s College London, discusses leukapheresis manufacturing approach in head and neck cancer.

In a study on CAR T cells in head and neck cancer, leukapheresis was done on patients. It allowed researchers to use CAR 4αβ that was co-expressed with the CAR to manufacture cell product with a 100% success rate to date, from as little to 14 mL of whole blood to normally 120 mL of whole blood.

This is an expensive manufacturing approach, though, and it takes a long time. But, in this trial, Papa says, it was done with a blood draw—less than what would be taken in a blood donation.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Publication Bottom Border
Border Publication